InvestorsHub Logo
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: willyw post# 2193

Monday, 04/25/2022 10:23:37 AM

Monday, April 25, 2022 10:23:37 AM

Post# of 2948
Shionogi PR re COVID antiviral fails to mention teratogenicity!

https://www.businesswire.com/news/home/20220423005001/en

Shionogi is evidently acting like MRK did with Molnupiravir—i.e. pretending that a safety issue does not exist. In MRK’s case, the result was a product with essentially no demand because the FDA EUA restricts usage to patients “for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate” (#msg-167236732).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News